LongeVC portfolio company Rubedo Life Sciences has secured FDA IND clearance for RLS-1496, a first-in-class small molecule drug candidate targeting dermatological conditions, including plaque psoriasis and atopic dermatitis.
Rubedo takes a pragmatic approach to cellular senescence, developing disease-modifying therapies with clear regulatory pathways. Their AI-driven drug discovery platform ALEMBIC™ identifies specific cellular targets in aging tissue and develops selective medicines around them.
The IND clearance represents an important milestone for the company's therapeutic strategy, advancing both our understanding of aging and the development of targeted interventions.
Congratulations to Frederick Beddingfield MD, PhD, Marco Quarta, and the entire Rubedo team on this achievement.
Rubedo takes a pragmatic approach to cellular senescence, developing disease-modifying therapies with clear regulatory pathways. Their AI-driven drug discovery platform ALEMBIC™ identifies specific cellular targets in aging tissue and develops selective medicines around them.
The IND clearance represents an important milestone for the company's therapeutic strategy, advancing both our understanding of aging and the development of targeted interventions.
Congratulations to Frederick Beddingfield MD, PhD, Marco Quarta, and the entire Rubedo team on this achievement.
Read more here.